Connor, Clark & Lunn Investment Management (CC&L)’s Stemline Therapeutics, Inc. STML Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,125	Closed	-$123K	–	892
2017 Q3	$123K	Sell	11,125 -1,700	-13%	-$16K	﹤0.01%	777
2017 Q2	$118K	Buy	+12,825	New	+$107K	﹤0.01%	781
2016 Q2	–	Sell	-10,500	Closed	-$49K	–	963
2016 Q1	$49K	Sell	10,500 -6,700	-39%	-$32.7K	﹤0.01%	798
2015 Q4	$109K	Buy	17,200 +7,100	+70%	+$57.6K	﹤0.01%	751
2015 Q3	$89K	Sell	10,100 -1,500	-13%	-$15.7K	﹤0.01%	672
2015 Q2	$137K	Hold	11,600	–	–	﹤0.01%	578
2015 Q1	$168K	Buy	+11,600	New	+$178K	﹤0.01%	516

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s STML Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 11,125 shares — an estimated $123K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in STML in Q1 2015 and held it in 7 quarters. The position peaked at $168K in Q1 2015. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 11,125 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $123K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Stemline Therapeutics, Inc. position peaked at $168K in Q1 2015.
80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.